ELTXElicio Therapeutics, Inc.vs its industry peers
A metric-by-metric comparison of Elicio Therapeutics, Inc. against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| 기업 | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ELTX본 종목 | $47M#4 | — | 5.9x#6 | 20.2x#3 | -91.9%#5 | 23.8%#5 | -1639.0%#3 | -498.6%#6 | — | — | -84.3%#6 | — |
| XLO | $52M#1 | — | 0.7x#2 | 1.2x#1 | 589.9%#2 | 39.8%#3 | -95.9%#1 | -48.5%#3 | — | — | -15.4%#1 | — |
| HYPD | $51M#2 | — | 0.5x#1 | 62.3x#5 | 1318.8%#1 | 9.0%#7 | -5743.5%#4 | -44.5%#2 | -46.8%#1 | — | -71.9%#5 | — |
| CLNN | $50M#3 | — | — | 248.0x#6 | -41.5%#4 | 33.6%#4 | -11541.5%#5 | — | — | — | -39.1%#3 | — |
| HOWL | $46M#5 | — | 2.8x#5 | — | — | 13.7%#6 | — | -373.3%#5 | -229.9%#3 | — | -34.6%#2 | — |
| ANVS | $46M#6 | — | — | — | — | -17.3%#8 | — | — | — | — | -54.8%#4 | — |
| MCRB | $42M#7 | — | 1.2x#3 | 53.4x#4 | — | 4088.2%#1 | -11910.1%#6 | 16.5%#1 | -72.9%#2 | — | — | — |
| VERU | $40M#8 | — | 1.4x#4 | 2.4x#2 | 3.6%#3 | 39.9%#2 | -146.6%#2 | -80.1%#4 | -399.3%#4 | — | — | 0.0%#1 |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. 이 표는 생성 중 시간이 초과되어 그룹의 일부만 포함합니다. 순위는 표시된 행 내에서만 유효하며 곧 채워집니다. Table built 2026-09-17.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice